1. Home
  2. CSTL vs JQC Comparison

CSTL vs JQC Comparison

Compare CSTL & JQC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$32.37

Market Cap

722.8M

Sector

Health Care

ML Signal

HOLD

Logo Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

JQC

Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

HOLD

Current Price

$4.73

Market Cap

705.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSTL
JQC
Founded
2007
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
722.8M
705.1M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
CSTL
JQC
Price
$32.37
$4.73
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$45.50
N/A
AVG Volume (30 Days)
310.1K
584.6K
Earning Date
05-06-2026
01-01-0001
Dividend Yield
N/A
11.13%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$344,229,000.00
N/A
Revenue This Year
$2.42
N/A
Revenue Next Year
$12.69
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.66
N/A
52 Week Low
$17.72
$4.62
52 Week High
$44.28
$5.46

Technical Indicators

Market Signals
Indicator
CSTL
JQC
Relative Strength Index (RSI) 54.54 40.91
Support Level $22.88 $4.69
Resistance Level $34.23 $4.88
Average True Range (ATR) 1.54 0.03
MACD -0.42 -0.00
Stochastic Oscillator 23.40 0.00

Price Performance

Historical Comparison
CSTL
JQC

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

About JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.

Share on Social Networks: